Effect of apolipoprotein E4 on clinical, neuroimaging, and biomarker measures in noncarrier participants in the Dominantly Inherited Alzheimer Network
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
The apolipoprotein E ε4 allele (APOE4) is the major genetic risk factor for sporadic Alzheimer Disease (AD). APOE4 may have effects on cognition and brain atrophy years before the onset of symptomatic AD. We analyzed the effects of APOE4 in a unique cohort of young adults who had undergone comprehensive assessments as part of the Dominantly Inherited Alzheimer Network (DIAN), an international longitudinal study of individuals from families with Autosomal Dominant AD. We analyzed the effect of an APOE4 allele on cognitive measures, volumetric MRI, amyloid deposition, glucose metabolism and on cerebrospinal fluid levels of AD biomarkers in 162 participants that did not carry the mutant gene (non-carriers). APOE4+ and APOE4− mutation non-carriers had similar performance on cognitive measures. Amyloid deposition began at an earlier age in APOE4+ participants, while hippocampal volume was similar between the groups. These preliminary findings are consistent with growing evidence that the APOE4 allele may exert effects in mid-life years before symptom onset, promoting amyloid deposition before altering cognitive performance or brain structure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814 · cited 1×
“The DIAN study has been useful in this regard (Bateman et al., 2012; Benzinger et al., 2013; Cash et al., 2013; Fagan et al., 2014; Wang et al., 2015), as have large cohorts in sporadic AD, including the Alzheimer Disease Neuroimaging Initiative (ADNI, reviewed in Weiner et al.”
MethodSelf-citationTrail Making Test A and B: normative data stratified by age and education
Tombaugh, T. (2004) · Archives of Clinical Neuropsychology · doi:10.1016/s0887-6177(03)00039-8 · Cited by 3,239 · cited 1×
“The association of age with performance on speeded tasks (Trail Making A and B) was consistent with prior studies (Tombaugh, 2004).”
ResultPrevalence of Cerebral Amyloid Pathology in Persons Without Dementia: A Meta-analysis
Jansen, W. J., Ossenkoppele, R., Knol, D. L., Tijms, B. M., Scheltens, P., Verhey, F. R. J., Visser, P. J., Aalten, P., Aarsland, D., Alcolea, D., et al. (2015) · JAMA · doi:10.1001/jama.2015.4668 · Cited by 1,610
Self-citationReiman, E. M., Caselli, R. J., Yun, L. S., Chen, K., Bandy, D., Minoshima, S., Thibodeau, S. N., & Osborne, D. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603213341202 · Cited by 1,366
Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging
Rowe, C. C., Ellis, K. A., Rimajova, M., Bourgeat, P., Pike, K. E., Jones, G., Fripp, J., Tochon-Danguy, H., Morandeau, L., O'Keefe, G., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.007 · Cited by 986 · cited 1×
“Amyloid deposition in precuneus and in cortex overall was stable with age for APOE4 noncarriers while APOE4 carriers had increasing amyloid deposition with age, consistent with prior reports in older cohorts (Liu et al., 2016; Rowe et al., 2010).”
ResultFunctional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia
Reiman, E. M., Chen, K., Alexander, G. E., Caselli, R. J., Bandy, D., Osborne, D., Saunders, A. M., & Hardy, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2635903100 · Cited by 977
Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease
Villemagne, V. L., Pike, K. E., Chételat, G., Ellis, K. A., Mulligan, R. S., Bourgeat, P., Ackermann, U., Jones, G., Szoeke, C., Salvado, O., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22248 · Cited by 833
APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging
Morris, J. C., Roe, C. M., Xiong, C., Fagan, A. M., Goate, A. M., Holtzman, D. M., & Mintun, M. A. (2010) · Annals of Neurology · doi:10.1002/ana.21843 · Cited by 830
Self-citationMorris, J. C., Roe, C. M., Grant, E. A., Head, D., Storandt, M., Goate, A. M., Fagan, A. M., Holtzman, D. M., & Mintun, M. A. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.269 · Cited by 476
Self-citationLongitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer’s Disease
Fagan, A. M., Xiong, C., Jasielec, M. S., Bateman, R. J., Goate, A. M., Benzinger, T. L. S., Ghetti, B., Martins, R. N., Masters, C. L., Mayeux, R., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007901 · Cited by 434 · cited 2×
“The DIAN study has been useful in this regard (Bateman et al., 2012; Benzinger et al., 2013; Cash et al., 2013; Fagan et al., 2014; Wang et al., 2015), as have large cohorts in sporadic AD, including the Alzheimer Disease Neuroimaging Initiative (ADNI, reviewed in Weiner et al.”
MethodSelf-citation
Cited by
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
Flowers, S. A., & Rebeck, G. W. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104724 · Cited by 149
Wang, Y.-Y., Ge, Y.-J., Tan, C.-C., Cao, X.-P., Tan, L., & Xu, W. (2021) · Journal of Alzheimer's Disease · doi:10.3233/jad-201606 · Cited by 49
“…further enhanced by lines of evidence from longitudinal studies regarding cerebrospinal fluid (CSF) or brain positron-emission tomography (PET), such that APOE4 allele carriers developed cerebral amyloid-(cid:2) (A (cid:2) )depositionatamorerapidratethannon-carriers, even at an earlier age [9, 10].”
A multi‐hit hypothesis for an APOE4 ‐dependent pathophysiological state
Steele, O. G., Stuart, A. C., Minkley, L., Shaw, K., Bonnar, O., Anderle, S., Penn, A. C., Rusted, J., Serpell, L., Hall, C., et al. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15685 · Cited by 44
“…with late-age reductions in regional brain volume in the hippocampus and medial temporal lobe, although this is not always replicated and the influence of APOE isoform at younger age remains unclear (e.g., Bussy et al., 2019; Cherbuin et al., 2007; Evans et al., 2020; Flowers & Rebeck, 2020).”
BackgroundMicroRNAs in Extracellular Vesicles of Alzheimer’s Disease
Li, W., & Zheng, Y. (2023) · Cells · doi:10.3390/cells12101378 · Cited by 43
Metadata
- Authors
- Bussy, A., Snider, B. J., Coble, D., Xiong, C., Fagan, A. M., Cruchaga, C., Benzinger, T. L. S., Gordon, B. A., Hassenstab, J., Bateman, R. J., & Morris, J. C.
- Venue
- Neurobiology of Aging
- Publisher
- Elsevier BV
- Published
- 2019-03
- Volume
- 75
- Pages
- 42-50
- ISSN
- 0197-4580 (ISSN-L)
- OpenAlex
- W2896756073
- Cited by
- 54
- References
- 25
- FWCI
- 5.03
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of apolipoprotein E4 on clinical, neuroimaging, and biomarker measures in noncarrier participants in the Dominantly Inherited Alzheimer Network. https://app.cochat.ai/papers/10.1016/j.neurobiolaging.2018.10.011
- The paper
- Bussy, A., Snider, B. J., Coble, D., Xiong, C., Fagan, A. M., Cruchaga, C., Benzinger, T. L. S., Gordon, B. A., Hassenstab, J., Bateman, R. J., & Morris, J. C. (2019). Effect of apolipoprotein E4 on clinical, neuroimaging, and biomarker measures in noncarrier participants in the Dominantly Inherited Alzheimer Network. Neurobiology of Aging. https://doi.org/10.1016/j.neurobiolaging.2018.10.011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.